These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31744893)

  • 1. The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors.
    Samaranayake GJ; Troccoli CI; Zhang L; Huynh M; Jayaraj CJ; Ji D; McPherson L; Onishi Y; Nguyen DM; Robbins DJ; Karbaschi M; Cooke MS; Barrientos A; Kool ET; Rai P
    Mol Cancer Ther; 2020 Feb; 19(2):432-446. PubMed ID: 31744893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.
    McPherson LA; Troccoli CI; Ji D; Bowles AE; Gardiner ML; Mohsen MG; Nagathihalli NS; Nguyen DM; Robbins DJ; Merchant NB; Kool ET; Rai P; Ford JM
    DNA Repair (Amst); 2019 Nov; 83():102644. PubMed ID: 31311767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OGG1 co-inhibition antagonizes the tumor-inhibitory effects of targeting MTH1.
    Zhang L; Misiara L; Samaranayake GJ; Sharma N; Nguyen DM; Tahara YK; Kool ET; Rai P
    Redox Biol; 2021 Apr; 40():101848. PubMed ID: 33450725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.
    Kawamura T; Kawatani M; Muroi M; Kondoh Y; Futamura Y; Aono H; Tanaka M; Honda K; Osada H
    Sci Rep; 2016 May; 6():26521. PubMed ID: 27210421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
    Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
    BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation and development of MTH1 inhibitors for treatment of cancer.
    Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
    Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
    Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
    EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
    Gad H; Koolmeister T; Jemth AS; Eshtad S; Jacques SA; Ström CE; Svensson LM; Schultz N; Lundbäck T; Einarsdottir BO; Saleh A; Göktürk C; Baranczewski P; Svensson R; Berntsson RP; Gustafsson R; Strömberg K; Sanjiv K; Jacques-Cordonnier MC; Desroses M; Gustavsson AL; Olofsson R; Johansson F; Homan EJ; Loseva O; Bräutigam L; Johansson L; Höglund A; Hagenkort A; Pham T; Altun M; Gaugaz FZ; Vikingsson S; Evers B; Henriksson M; Vallin KS; Wallner OA; Hammarström LG; Wiita E; Almlöf I; Kalderén C; Axelsson H; Djureinovic T; Puigvert JC; Häggblad M; Jeppsson F; Martens U; Lundin C; Lundgren B; Granelli I; Jensen AJ; Artursson P; Nilsson JA; Stenmark P; Scobie M; Berglund UW; Helleday T
    Nature; 2014 Apr; 508(7495):215-21. PubMed ID: 24695224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of MTH1 inhibition-induced DNA strand breaks: The slippery slope from the oxidized nucleotide pool to genotoxic damage.
    Rai P; Sobol RW
    DNA Repair (Amst); 2019 May; 77():18-26. PubMed ID: 30852368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTH1 Inhibitor TH287 Suppresses Gastric Cancer Development Through the Regulation of PI3K/AKT Signaling.
    Zhan D; Zhang X; Li J; Ding X; Cui Y; Jia J
    Cancer Biother Radiopharm; 2020 Apr; 35(3):223-232. PubMed ID: 32077746
    [No Abstract]   [Full Text] [Related]  

  • 11. A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target.
    Ji D; Beharry AA; Ford JM; Kool ET
    J Am Chem Soc; 2016 Jul; 138(29):9005-8. PubMed ID: 27413803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and specific MTH1 inhibitors targeting gastric cancer.
    Zhou W; Ma L; Yang J; Qiao H; Li L; Guo Q; Ma J; Zhao L; Wang J; Jiang G; Wan X; Adam Goscinski M; Ding L; Zheng Y; Li W; Liu H; Suo Z; Zhao W
    Cell Death Dis; 2019 Jun; 10(6):434. PubMed ID: 31164636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
    Pompsch M; Vogel J; Classen F; Kranz P; Iliakis G; Riffkin H; Brockmeier U; Metzen E
    BMC Cancer; 2018 Nov; 18(1):1190. PubMed ID: 30497423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potent and selective MTH1 inhibitors.
    Petrocchi A; Leo E; Reyna NJ; Hamilton MM; Shi X; Parker CA; Mseeh F; Bardenhagen JP; Leonard P; Cross JB; Huang S; Jiang Y; Cardozo M; Draetta G; Marszalek JR; Toniatti C; Jones P; Lewis RT
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1503-1507. PubMed ID: 26898335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitotic MTH1 Inhibitors in Treatment of Cancer.
    Helleday T
    Cancer Treat Res; 2023; 186():223-237. PubMed ID: 37978139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTH1 expression is required for effective transformation by oncogenic HRAS.
    Giribaldi MG; Munoz A; Halvorsen K; Patel A; Rai P
    Oncotarget; 2015 May; 6(13):11519-29. PubMed ID: 25893378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1.
    Lee Y; Onishi Y; McPherson L; Kietrys AM; Hebenbrock M; Jun YW; Das I; Adimoolam S; Ji D; Mohsen MG; Ford JM; Kool ET
    ACS Chem Biol; 2022 Aug; 17(8):2074-2087. PubMed ID: 35830623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma.
    Li X; Li L; Huang Y; Liu B; Chi H; Shi L; Zhang W; Li G; Niu Y; Zhu X
    Biomater Sci; 2017 Sep; 5(10):2068-2078. PubMed ID: 28744533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
    Huber KV; Salah E; Radic B; Gridling M; Elkins JM; Stukalov A; Jemth AS; Göktürk C; Sanjiv K; Strömberg K; Pham T; Berglund UW; Colinge J; Bennett KL; Loizou JI; Helleday T; Knapp S; Superti-Furga G
    Nature; 2014 Apr; 508(7495):222-7. PubMed ID: 24695225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.
    Patel A; Burton DG; Halvorsen K; Balkan W; Reiner T; Perez-Stable C; Cohen A; Munoz A; Giribaldi MG; Singh S; Robbins DJ; Nguyen DM; Rai P
    Oncogene; 2015 May; 34(20):2586-96. PubMed ID: 25023700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.